Navigation Links
GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
Date:11/12/2008

LONDON, Nov. 12 /PRNewswire-FirstCall/ -- GlaxoSmithKline (LSE/NYSE: GSK) announced today that Gemstone Acquisition Corporation, a wholly-owned subsidiary of GSK, is commencing a cash tender offer to purchase all outstanding shares of common stock of Genelabs Technologies, Inc. (Nasdaq: GNLB), for $1.30 in cash without interest and less any required withholding taxes. The tender offer is being made pursuant to a previously announced Agreement and Plan of Merger dated October 29, 2008 among Genelabs, Gemstone and SmithKline Beecham Corporation, a wholly-owned subsidiary of GSK.

The Genelabs board of directors has unanimously determined that the tender offer and the merger are fair to, and in the best interests of, Genelabs and the shareholders of Genelabs and adopted and approved the merger agreement, the tender offer and the merger. The Genelabs board of directors unanimously declared the advisability of the merger agreement and recommends that Genelabs' shareholders tender their shares pursuant to the tender offer.

The tender offer will expire at 12:00 midnight EST on Wednesday, December 10, 2008, unless extended in accordance with the merger agreement and the applicable rules and regulations of the Securities and Exchange Commission (SEC). The offer is subject to various conditions, including the acquisition by GSK of 90 percent of the outstanding shares of Genelabs' common stock on a fully diluted basis.

GSK today will file with the SEC a tender offer statement on Schedule TO setting forth in detail the terms of the tender offer. Genelabs today will file with the SEC a solicitation/ recommendation statement on Schedule 14D-9 setting forth in detail, among other things, the recommendation of Genelabs' board of directors that Genelabs' shareholders accept the tender offer and tender their shares pursuant to the tender offer. Questions and requests for assistance may be directed to the Information Agent for the offer, MacKenzie Partners, Inc., at (212) 929-5500 or (800) 322-2885 (toll free).

About GlaxoSmithKline plc

GlaxoSmithKline plc -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information including a copy of this announcement and details of the company's updated product development pipeline, visit GSK at http://www.gsk.com.

About Genelabs

Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus. For more information, please visit http://www.genelabs.com.

Cowen and Company was the exclusive financial advisor to Genelabs in this transaction.

This announcement and the description contained herein is neither an offer to purchase nor a solicitation of an offer to sell shares of Genelabs. GSK and Gemstone Acquisition Corporation are filing with the SEC a tender offer statement on Schedule TO containing an offer to purchase, forms of letters of transmittal and other documents relating to the tender offer, and Genelabs is filing with the SEC a solicitation/recommendation statement on Schedule 14D-9, with respect to the tender offer. GSK, Gemstone Acquisition Corporation and Genelabs are mailing these documents to the shareholders of Genelabs. These documents contain important information about the tender offer and shareholders of Genelabs are urged to read them carefully. Shareholders of Genelabs will be able to obtain a free copy of these documents (when they become available) and other documents filed by Genelabs or GSK with the SEC at the website maintained by the SEC at http://www.sec.gov. In addition, shareholders will be able to obtain a free copy of these documents (when they become available) from Genelabs by contacting Genelabs at 505 Penobscot Drive, Redwood City, California 94063.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2007.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
4. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
5. GlaxoSmithKline To Post Quarterly US Grants Report
6. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
7. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
8. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
9. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
10. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
11. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising treatments in ... the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient ... this year following FDA approval of a second application for a single patient, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board of Investment’s ... in San Francisco. Located at booth number 7301, representatives from the Thai Government, ... discuss the Thai biotechnology and life sciences sector. , Deputy Secretary General ...
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens say they ... may be hampering the research that could lead to one good one. Surviving Mesothelioma ... it now. , The team evaluated 98 mesothelioma patients who got ...
(Date:5/24/2016)... Worcester, Mass. (PRWEB) , ... May 24, 2016 ... ... including heart attacks, diabetes, and traumatic injuries, will be accelerated by research at ... skin cells into engines of wound healing and tissue regeneration. , The novel ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):